These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 36206622)
1. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622 [TBL] [Abstract][Full Text] [Related]
2. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related]
3. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800 [TBL] [Abstract][Full Text] [Related]
4. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547 [TBL] [Abstract][Full Text] [Related]
5. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719 [TBL] [Abstract][Full Text] [Related]
6. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study. Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ Front Immunol; 2023; 14():1120556. PubMed ID: 36936965 [TBL] [Abstract][Full Text] [Related]
7. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989 [TBL] [Abstract][Full Text] [Related]
8. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
9. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049 [TBL] [Abstract][Full Text] [Related]
10. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD; Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223 [TBL] [Abstract][Full Text] [Related]
12. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M Front Immunol; 2022; 13():811020. PubMed ID: 35126395 [TBL] [Abstract][Full Text] [Related]
13. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2022 Jun; 84(6):795-813. PubMed ID: 35405168 [TBL] [Abstract][Full Text] [Related]
14. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD; J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454 [TBL] [Abstract][Full Text] [Related]
15. Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. Orlandi C; Stefanetti G; Barocci S; Buffi G; Diotallevi A; Rocchi E; Ceccarelli M; Peluso S; Vandini D; Carlotti E; Magnani M; Galluzzi L; Casabianca A Viruses; 2023 May; 15(5):. PubMed ID: 37243247 [TBL] [Abstract][Full Text] [Related]
16. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose. Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064 [TBL] [Abstract][Full Text] [Related]
18. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811 [TBL] [Abstract][Full Text] [Related]
19. Waning of humoral immunity depending on the types of COVID-19 vaccine. Lim SY; Kim JY; Jung J; Yun SC; Kim SH Infect Dis (Lond); 2023 Mar; 55(3):216-220. PubMed ID: 36625442 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. Parry H; Bruton R; Tut G; Ali M; Stephens C; Greenwood D; Faustini S; Hughes S; Huissoon A; Meade R; Brown K; Amirthalingam G; Otter A; Hallis B; Richter A; Zuo J; Moss P Lancet Healthy Longev; 2021 Sep; 2(9):e554-e560. PubMed ID: 34401865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]